Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis
By, Admin1 min read
Share
Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the launch of the NAV3-33 Phase 3 clinical trial titled
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
